The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01<sub>E</sub>.
Ali MS. et al, (2025), NPJ vaccines, 10
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Venkatraman N. et al, (2025), The Lancet. Microbe
R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.
Kibwana E. et al, (2025), Front Immunol, 16
Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.
Bundi C. et al, (2025), Frontiers in immunology, 16
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.
Stockdale LK. et al, (2025), NPJ vaccines, 10
Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults
Silman D. et al, (2024), Wellcome Open Research, 9, 734 - 734
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.
Hanboonkunupakarn B. et al, (2024), NPJ vaccines, 9
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response
Mentzer AJ. et al, (2024), Nature Medicine, 30, 1384 - 1394
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N. et al, (2024), The Lancet. Infectious diseases, 24, 465 - 475
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo MS. et al, (2024), The Lancet, 403, 533 - 544
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination
Yin Z. et al, (2023), Cell Reports, 42, 112470 - 112470
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287
A tool for evaluating heterogeneity in avidity of polyclonal antibodies.
Li K. et al, (2023), Frontiers in immunology, 14